United States securities and exchange commission logo





                             August 4, 2022

       Jonathan Kaufman
       Chief Executive Officer
       Lipella Pharmaceuticals Inc.
       7800 Susquehanna St., Suite 505
       Pittsburgh, PA 15208

                                                        Re: Lipella
Pharmaceuticals Inc.
                                                            Registration
Statement on Form S-1
                                                            Filed July 29, 2022
                                                            File No. 333-266397

       Dear Mr. Kaufman:

              We have reviewed your registration statement and have the
following comments. In
       some of our comments, we may ask you to provide us with information so
we may better
       understand your disclosure.

              Please respond to this letter by amending your registration
statement and providing the
       requested information. If you do not believe our comments apply to your
facts and
       circumstances or do not believe an amendment is appropriate, please tell
us why in your
       response.

              After reviewing any amendment to your registration statement and
the information you
       provide in response to these comments, we may have additional comments.

       Registration Statement on Form S-1 filed July 29, 2022

       Our Product Pipeline, page 2

   1.                                                   Please revise your
pipeline table to include separate columns for each material stage you
                                                        will need to complete
before marketing your products. For instance, include separate
                                                        columns for each of
Phase 1, Phase 2, and Phase 3.
       Underwriting, page 94

   2.                                                   We note your inclusion
of Spartan Capital Securities, LLC in the underwriting table on
                                                        page 94. Please update
your narrative disclosure to here to discuss their role in the
                                                        proposed transaction or
otherwise advise. In addition, we note your disclosure that Spartan
                                                        Capital Securities, LLC
appears to hold over 9% of your common stock. Please describe
                                                        this relationship in
the underwriting section. Refer to Item 508 of Regulation S-K.
 Jonathan Kaufman
Lipella Pharmaceuticals Inc.
August 4, 2022
Page 2

        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

       Refer to Rules 460 and 461 regarding requests for acceleration. Please
allow adequate
time for us to review any amendment prior to the requested effective date of
the registration
statement.

       You may contact Eric Atallah at 202-551-3663 or Jeanne Baker at
202-551-3691 if you
have questions regarding comments on the financial statements and related
matters. Please
contact Jason Drory at 202-551-8342 or Anne Parker at 202-551-3611 with any
other questions.



                                                           Sincerely,
FirstName LastNameJonathan Kaufman
                                                           Division of
Corporation Finance
Comapany NameLipella Pharmaceuticals Inc.
                                                           Office of Life
Sciences
August 4, 2022 Page 2
cc:       Michael DeDonato, Esq.
FirstName LastName